Cartesian Therapeutics (RNAC) Change in Receivables (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Change in Receivables of -$854000.0 for Q1 2026, down 195.63% year-over-year from $893000.0 in Q1 2025, and down 317.3% quarter-over-quarter from $393000.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Change in Receivables (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Change in Receivables data on file, last reported at -$854000.0 in Q1 2026.
- Change in Receivables for Q1 2026 came in at -$854000.0, down 195.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.5 million (down 524.07% YoY), and the FY2025 annual result was $243000.0, up 104.86% from the prior year.
- Change in Receivables fell to -$854000.0 in Q1 2026 per RNAC's latest filing, from $393000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $30.0 million in Q2 2024 and troughed at -$27.2 million in Q3 2024.
- A 5-year average of -$567823.5 and a median of -$487000.0 in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2024: Change in Receivables soared 13591.87% in 2022, then plunged 5487.27% in 2024.
- A 5-year view of Change in Receivables shows it stood at -$329000.0 in 2022, then jumped by 395.44% to $972000.0 in 2023, then plunged by 507.1% to -$4.0 million in 2024, then jumped by 109.93% to $393000.0 in 2025, then plunged by 317.3% to -$854000.0 in 2026.
- Business Quant data shows RNAC's Change in Receivables at -$854000.0 in Q1 2026, $393000.0 in Q4 2025, and $368000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | -854,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -854,000.00 |
| Mar 31, 2026 | -854,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Sep 30, 2025 | 368,000.00 |
| Sep 30, 2025 | 368,000.00 |
| Jun 30, 2025 | -1.41 Mn |
| Jun 30, 2025 | -1.41 Mn |
| Mar 31, 2025 | 893,000.00 |
| Mar 31, 2025 | 893,000.00 |
| Dec 31, 2024 | -3.96 Mn |
| Dec 31, 2024 | -3.96 Mn |
| Sep 30, 2024 | -27.21 Mn |
| Sep 30, 2024 | -27.21 Mn |
| Jun 30, 2024 | 30.03 Mn |
| Jun 30, 2024 | 30.03 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | 972,000.00 |
| Dec 31, 2023 | 972,000.00 |